Morepen Laboratories Limited

MOREPENLAB

INE083A01026

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 06:00:46 2024-05-15 am EDT			5-day change	1st Jan Change
46.7 ^INR	+0.69%		+0.32%	-3.77%

Mar. 30	Morepen Laboratories Limited Announces Resignation of Lalit Kumar Baregama, Chief Growth Officer	CI
Mar. 01	Morepen Laboratories Limited Announces the Promotion of Amita Sharma to Chief Operating Officer -API	CI

Morepen Laboratories Limited Announces Resignation of Anju Suri as Director (Non-Executive, Non-Independent)

June 22, 2022 at 10:29 am EDT

Morepen Laboratories Limited announced that Mrs. Anju Suri vide her letter dated June 22, 2022 has resigned from the Board of the Company as Director (Non-Executive, Non-Independent) with effect from close of business hours of June 22, 2022. The reason resignation is personal reasons.

Latest news about Morepen Laboratories Limited

Morepen Laboratories Limited Announces Resignation of Lalit Kumar Baregama, Chief Growth Officer	Mar. 30	CI
Morepen Laboratories Limited Announces the Promotion of Amita Sharma to Chief Operating Officer -API	Mar. 01	CI
Morepen Laboratories Limited Approves the Appointment of Vikas Sharma, Talent Acquisition & HRBP, Functional Head	Jan. 31	CI
Morepen Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Jan. 31	CI
Morepen Laboratories Limited Announces Resignation of Rolli Saxena, General Manager - HR, Being A Functional Head and Senior Management Personnel	Dec. 01	CI
Morepen Laboratories Limited Appoints Shantanu Tuli as President -Strategy and Brand Identity, Effective from December 1, 2023	Nov. 30	CI
Morepen Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 02	CI
Morepen Laboratories to Transfer Formulation Distribution and Marketing Business to Subsidiary	23-08-15	MT
Morepen Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-05	CI
Morepen Laboratories' Net Profit Drops in Fiscal Q4	23-05-16	MT
Morepen Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	23-05-16	CI
US FDA Clears Morepen Laboratories' Baddi, India	23-03-27	MT
Morepen Laboratories Forms Wholly-Owned Subsidiary	23-03-20	MT
Morepen Laboratories Limited Announces Incorporation of Wholly Owned Subsidiary	23-03-17	CI
Morepen Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-13	CI
Morepen Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	22-11-10	CI
Morepen Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	22-07-29	CI
Morepen Laboratories Limited Announces Resignation of Anju Suri as Director (Non-Executive, Non-Independent)	22-06-22	CI
Morepen Laboratories Limited announced that it has received INR 1.1465201 billion in funding from a group of investors	22-05-08	CI
Morepen Laboratories Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2022	22-05-05	CI
Morepen Laboratories Sees Drop in Fiscal Q4 Consolidated Net Profit	22-05-05	MT
Morepen Laboratories Limited Reports Earnings Results for the Full Year Ended March 31, 2022	22-05-05	CI
Morepen Laboratories Limited Announces Cessation of Arun Kumar Sinha as Whole Time Director	22-04-01	CI
Morepen Laboratories Posts Decline in Fiscal Q3 Consolidated Net Profit	22-02-09	MT
Morepen Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	22-02-08	CI

Chart Morepen Laboratories Limited

Duration

Period

More charts

Company Profile

Morepen Laboratories Limited is a pharmaceutical company. The Company is in the business of manufacturing, producing, developing and marketing a range of active pharmaceutical ingredients (APIs), branded and generic formulations and also home health products. Its APIs include Apixaban, Edoxaban, Linagliptin, Linagliptin + Metformin, Empagliflozin, Empagliflozin + Metformin, Atorvastatin, Rosuvastain, Rivaroxaban, Febuxostat, Montelukast (Oral), Montelukast (Chewable), among others. Its finished formulations include Intebact Capsules, Intelicaps Lax, Rythmix Kid Drop, Rythmix Kid Syrup, Kompact Powder, Saltum and Acifix 3X Suspension among others. Its home health products include Dr. Morepen 49W Room Air Purifier with HEPA Filter, Dr. Morepen VP06 Breathe Free Vaporizer, Dr. Morepen CN06 Compressor Nebulizer and Dr. Morepen ST03 Dual Head Stethoscope, among others. Its subsidiaries include Dr. Morepen Limited, Morepen Devices Limited, and Total Care Limited.

Sector

Pharmaceuticals

Calendar

2024-07-24 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
MOREPEN LABORATORIES LIMITED	-3.77%	284M
NOVO NORDISK A/S	+31.37%	588B
JOHNSON & JOHNSON	-2.81%	364B
MERCK & CO., INC.	+20.51%	326B
ABBVIE INC.	+5.53%	285B
ASTRAZENECA PLC	+14.83%	239B
NOVARTIS AG	+9.93%	210B
ROCHE HOLDING AG	-6.95%	200B
AMGEN INC.	+10.96%	167B
PFIZER, INC.	+0.19%	161B

Other Pharmaceuticals